• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xoma Royalty Corporation (NQ: XOMA )

    26.66 -0.10 (-0.37%)
    Streaming Delayed Price Updated: 9:30 AM EDT, Aug 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 404
    Open 26.66
    Bid (Size) 26.80 (1)
    Ask (Size) 27.89 (1)
    Prev. Close 26.76
    Today's Range 26.66 - 26.66
    52wk Range 13.48 - 30.36
    Shares Outstanding 11,625,826
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
    FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
    Via Benzinga
    Exposures Product Safety
    Demystifying XOMA: Insights From 5 Analyst Reviews
    Via Benzinga

    Performance

    YTD
    +27.62%
    +27.62%
    1 Month
    +7.07%
    +7.07%
    3 Month
    +3.25%
    +3.25%
    6 Month
    +33.50%
    +33.50%
    1 Year
    +66.00%
    +66.00%

    More News

    Read More
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
    From XOMA Corporation
    Via GlobeNewswire
    Peeling Back The Layers: Exploring XOMA Through Analyst Insights
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For XOMA
    Via Benzinga
    Recap: XOMA Q4 Earnings
    Via Benzinga
    3 Crazy Good Stocks to Buy With $500 Right Now
    Via InvestorPlace
    XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Corporation Announces Closing of Tender Offer
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at Upcoming Investor Conferences in March
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
    Via Benzinga
    XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
    From XOMA Corporation
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.